AstraZeneca: positive results in Wilson's disease

(CercleFinance.com) - AstraZeneca presented detailed results from a phase III clinical study of its ALXN1840 tablet in Wilson's disease on Thursday.


The biopharmaceutical company said that the drug, which is still in the experimental stage, met its primary endpoint by achieving three times the copper removal of the current reference treatment.

The company points out that the results were equally effective in patients treated for a decade.

This data will be presented at the International Liver Congress (ILC), which is currently being held in London.

Wilson's disease is a genetic disorder characterised by the toxic accumulation of copper in the body, mainly in the liver and brain, but also in other vital organs.

The share is rallying slightly on this news, currently up about 0.4% just over an hour from close in London.


Copyright (c) 2022 CercleFinance.com. All rights reserved.